Torii Pharma gains Japanese approval for Ycanth

Japanese pharma major Shionogi (TYO: 4507) announced that its subsidiary Torii Pharmaceutical has received manufacturing and marketing approval of Ycanth (cantharidin) topical solution 0.71% for the treatment of molluscum contagiosum, a dermatological disease, in Japan.

Ycanth topical solution 0.71% is a skin disease treatment drug containing cantharidin as an active ingredient. In the Phase III clinical study of Ycanth topical solution 0.71% in patients with molluscum contagiosum (≥2 years old) in Japan, the primary endpoint of efficacy has met superiority to the vehicle. Furthermore, the safety of Ycanth topical solution 0.71% was confirmed and there were no observed issues of tolerability for the application.

Torii expects Ycanth topical solution 0.71% to be a new option for the treatment of molluscum contagiosum patients (≥2 years old) in Japan.